Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.10.4147

Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities  

Daga, Aditi (Department of Microbiology, MVM Science College, Saurashtra University)
Ansari, Afzal (BIT virtual Institute of Bioinformatics (GCRI Node), GSBTM)
Patel, Shanaya (The Gujarat Cancer & Research Institute)
Mirza, Sheefa (The Gujarat Cancer & Research Institute)
Rawal, Rakesh (The Gujarat Cancer & Research Institute)
Umrania, Valentina (Department of Microbiology, MVM Science College, Saurashtra University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.10, 2015 , pp. 4147-4156 More about this Journal
Abstract
Lung cancer is a serious health problem and leading cause of death worldwide due to its high incidence and mortality. More than 80% of lung cancers feature a non-small cell histology. Over few decades, systemic chemotherapy and surgery are the only treatment options in this type of tumor but due to their limited efficacy and overall poor survival of patients, there is an urge to develop newer therapeutic strategies which circumvent the problems. Enhanced knowledge of translational science and molecular biology have revealed that lung tumors carry diverse driver gene mutations and adopt different intracellular pathways leading to carcinogenesis. Hence, the development of targeted agents against molecular subgroups harboring critical mutations is an attractive approach for therapeutic treatment. Targeted therapies are clearly more preferred nowadays over systemic therapies because they target tumor specific molecules resulting with enhanced activity and reduced toxicity to normal tissues. Thus, this review encompasses comprehensive updates on targeted therapies for the driver mutations in non-small cell lung cancer (NSCLC) and the potential challenges of acquired drug resistance faced i n the field of targeted therapy along with the imminent newer treatment modalities against lung cancer.
Keywords
Lung cancer; driver mutation; translocation; drug target; targeted therapy; acquired resistance; NSCLC;
Citations & Related Records
Times Cited By KSCI : 13  (Citation Analysis)
연도 인용수 순위
1 Chou PY, Huang GJ, Pan CH, et al (2011). Trilinolein inhibits proliferation of human non-small cell lung carcinoma A549 through the modulation of PI3K/Akt pathway. Am J Chin Med, 39, 803-15.   DOI
2 Cipriani NA, Abidoye OO, Vokes E, et al (2009). MET as a target for treatment of chest tumors. Lung Cancer, 63, 169-79.   DOI
3 Cooper WA, Lam DC, O’Toole SA, et al (2013). Molecular Biology of Lung Cancer. J Thorac Dis, 5, 479-90.
4 Cross DA, Ashton SE, Ghiorghiu S, et al (2014). AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov [Epub ahaed of print].
5 Cufi S, Bonavia R, Vazquez-Martin A, Oliveras-Ferraros C, et al (2013). Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Sci Rep, 3, 2459.   DOI
6 Da Cunha Santos G, Shepherd FA, Tsao MS (2011). EGFR mutations and lung cancer. Annu Rev Pathol, 6, 49-69.   DOI
7 D'Arcangelo M, D'Incecco A, Cappuzzo FE (2013). Rare mutations in non-small-cell lung cancer. Future Oncol, 9, 699-711.   DOI
8 Datta R, Halder SK, Zhang B. (2013). Role of TGF-${\beta}$ signaling in curcumin-mediated inhibition of tumorigenicity of human lung cancer cells. J Cancer Res Clin Oncol, 139, 563-72.   DOI
9 Davies KD, Le AT, Theodoro MF, et al (2012). Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res, 18, 4570-9.   DOI
10 Di BS, Wei KP, Tian JH, et al (2014). Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and metaanalysis. Asian Pac J Cancer Prev, 15, 3419-24.   DOI
11 Ellison G, Zhu G, Moulis A, et al (2013). EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol, 66, 79-89.   DOI
12 Engelman JA, Janne PA (2008) Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res, 14, 2895-9.   DOI
13 Ercan D, Zejnullahu K, Yonesaka K, et al (2010). Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene, 29, 2346-56.   DOI   ScienceOn
14 Fang H, Lin RY, Sun MX, et al (2014). Efficacy and survivalassociated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer. Asian Pac J Cancer Prev, 15, 10967-70.
15 Gainor JF, Shaw AT (2013). Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol, 31, 3987-96.   DOI
16 Gandhi L, Janne PA (2012). Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res, 18, 3737-42.   DOI
17 Hall RD, Gray JE, Chiappori AA (2013). Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control, 20, 22-31.   DOI
18 Hirschowitz EA, Foody T, Kryscio R (2004). Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol, 22, 2808-15.   DOI
19 Hou ZB, Lu KJ, Wu XL, et al (2014). In vitro and in vivo antitumor evaluation of berbamine for lung cancer treatment. Asian Pac J Cancer Prev, 15, 1767-9.   DOI   ScienceOn
20 Husain H, Rudin CM (2011) ALK-targeted therapy for lung cancer: ready for prime time. Oncology (Williston Park), 25, 597-601.
21 Ise N, Omi K, Nambara D, et al (2011). Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors. Anticancer Res, 31, 4155-61.
22 Janne PA, Shaw AT, Pereira JR,et al (2013). Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol, 14, 38-47.   DOI
23 Jemal A, Siegel R, Ward E, et al (2010). Cancer statistics. CA: Cancer J Clin, 60, 277-300.   DOI
24 Jessica M, Matteo GL, Silvia N (2006). MET inhibition in lung cancer. Transl Lung Cancer Res, 2, 23-39.
25 Jose ST, Viteri S, Molina MA, et al (2013). BRAF mutant nonsmall cell lung cancer and treatment with BRAF inhibitors. Transl Lung Cancer Res, 2, 244-50.
26 Karachaliou N, Mayo C, Costa C, et al (2013). KRAS Mutations in Lung Cancer. Clin Lung Cancer, 14, 205-14.   DOI
27 Katayama R, Shaw AT, Khan TM, et al (2012). Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med, 4, 120ra17.
28 Kim H, Yoo SB, Choe JY, et al (2011). Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol, 6, 1359-66.   DOI
29 Kiziltan HS, Bayir AG, Tastekin D, et al (2014). Outcome of daily cisplatin with thoracic chemoradiotherapy in advanced non-small cell lung cancer patients withcomorbid disorders: a pilot study. Asian Pac J Cancer Prev, 15, 8591-4.   DOI
30 Kobayashi S, Boggon TJ, Dayaram T, et al (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 352, 786-92.   DOI
31 Kris MG, Johnson BE and Kwiatkowski DJ (2011). Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol, 29, [Epub ahead of print].
32 Kwak EL, Bang YJ, Camidge DR, et al (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 363, 1693-703.   DOI
33 Laurie SA, Miller VA, Grant SC, et al (2005). Phase I study of green tea extract in patients with advanced lung cancer. Cancer Chemother Pharmacol, 55, 33-8.   DOI
34 Lee JY, Lee YM, Chang GC, et al (2011). Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: theversatile adjuvant for gefitinib therapy. PLoS One, 6, 23756.   DOI
35 Li D, Ambrogio L, Shimamura T, et al (2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 27, 4702-11.   DOI
36 Li Y, Zhang S, Geng JX, et al (2013). Curcumin inhibits human non-small cell lung cancer A549 cell proliferation through regulation of Bcl-2/Bax and cytochrome C. Asian Pac J Cancer Prev, 14, 4599-602.   DOI   ScienceOn
37 Linardou H, Dahabreh IJ, Kanaloupiti D, et al (2008). Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small cell lung cancer and metastatic colorectal cancer. Lancet Oncol, 9, 962-72.   DOI
38 Lu Y, Wei C, Xi Z (2014). Curcumin suppresses proliferation and invasion in non-small cell lung cancer by modulation of MTA1-mediated Wnt/${\beta}$-catenin pathway. In vitro Cell Dev Biol Anim, 50, 840-50.   DOI
39 Lipson D, Capelletti M, Yelensky R, et al (2012). Identification of New ALK and RET Gene Fusions from Colorectal and Lung Cancer Biopsies. Nature Med, 18, 382-4.   DOI   ScienceOn
40 Liu LZ, Fang J, Zhou Q, et al (2005). Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol, 68, 635-43.
41 Ma PC, Maulik G, Christensen J, et al (2003). c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev, 22, 309-25.   DOI
42 Ma PC, Tretiakova MS, MacKinnon AC, et al (2008). Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer, 47, 1025-37.   DOI
43 Ma YC, Li C, Gao F, et al (2014). Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway. Oncol Rep, 31, 1343-9.   DOI
44 Mao C, Qiu LX, Liao RY, et al (2010). KRAS mutations and resistance to EGFR-TKIs treatment in patients with nonsmall cell lung cancer: a meta-analysis of 22 studies. Lung Cancer, 69, 272-8.   DOI
45 Marchetti A, Felicioni L, Malatesta S, et al (2011). Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol, 29, 3574-9.   DOI   ScienceOn
46 Massarelli E, Varella-Garcia M, Tang X, et al (2007). KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res, 13, 2890-6.   DOI
47 Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57.   DOI
48 Mateen S, Raina K, Agarwal C, et al (2013). Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherinexpression together with inhibition of migration and invasion of human nonsmall cell lung cancer cells. J Pharmacol Exp Ther, 345, 206-14.   DOI
49 Mazieres J, Peters S, Lepage B, et al (2013). Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol, 31, 1997-2003.   DOI
50 Miller VA, Wakelee HA, Lara PN, et al (2008). Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial. J Clin Oncol, 26, 430.
51 Molina JR, Yang P, Cassivi SD, et al (2008). Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 83, 584-94.   DOI
52 Natukula K, Jamil K, Pingali UR, et al (2013). Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy incombination with paclitaxel, gemcitabine and etoposide. Asian Pac J Cancer Prev, 14, 4661-6.   DOI   ScienceOn
53 Ohashi K, Sequist LV, Arcila ME, et al (2012). Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutationsin KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A, 109, 2127-33.   DOI
54 Okuda K, Sasaki H, Yukiue H, et al (2008). Met gene copy number predicts the prognosis for completely resected nonsmall cell lung cancer. Cancer Sci, 99, 2280-5.   DOI   ScienceOn
55 Paik PK, Arcila ME, Fara M,et al (2011). Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol, 29, 2046-51.   DOI   ScienceOn
56 Osumi H, Matsusaka S, Shinozaki E, et al (2013). Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report. BMC Res Notes, 6, 508.   DOI
57 Ou SH, Bartlett CH, Mino-Kenudson M, et al (2012). A Success Story to Usher in the Second Decade of Molecular Targeted Therapy Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer. Oncologist, 17, 1351-75.   DOI
58 Oxnard GR, Binder A, Janne PA (2013). New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol, 31, 1097-104.   DOI
59 Pao W, Girard N (2011). New driver mutations in non-small-cell lung cancer. Lancet Oncol, 12, 175-80.   DOI
60 Pao W, Miller VA, Politi KA, et al (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2, 73.   DOI   ScienceOn
61 Pao W, Wang TY, Riely GJ, et al (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2, 17.   DOI   ScienceOn
62 Peter M. K. Westcott, Minh D (2013). The genetics and biology of KRAS in lung cancer. Chin J Cancer, 32, 63-70.   DOI
63 Pietanza MC, Lynch TJ, Lara PN, et al (2012). XL647-a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol, 7, 219- 226.   DOI
64 Robinson MJ, Cobb MH (1997). Mitogen-activated protein kinase pathways. Curr Opin Cell Biol, 9, 180-6.   DOI
65 Riely GJ, Marks J, Pao W (2009). KRAS mutations in non-small cell lung cancer. Proc Am Thorac So, 6, 201-5.   DOI
66 Rikova K, Guo A, Zeng Q, et al (2007). Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 131, 1190-203.   DOI
67 Robinson KW, Sandler AB (2013). The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. Oncologist, 18, 115-22.   DOI
68 Roengvoraphoj M, Tsongalis GJ, Dragnev KH, et al (2013). Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treat Rev, 39, 839-50.   DOI
69 Rolfo C, Passiglia F, Castiglia M, et al (2014). ALK and crizotinib: after the honeymoon what else? Resistance mechanisms and new therapies to overcome it. Transl Lung Cancer, [Epub ahead of print].
70 Samuels Y, Waldman T (2010). Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol, 347, 21-41.
71 Sarah Declerck, Johan Vansteenkiste (2014). Immunotherapy for lung cancer: ongoing clinical trials. Future Oncol, 10, 91-105.   DOI
72 Sarris EG, Saif MW, Syrigos KN (2012). The biological role of PI3K pathway in lung cancer. Pharmaceuticals (Basel), 5, 1236-64.   DOI
73 Sasaki H, Shimizu S, Tani Y, et al (2012). RET expression and detection of KIF5B/RET gene rearrangements in Japanese Lung cancer. Cancer Med, 1, 68-75.   DOI
74 Sequist LV, von Pawel J, Garmey EG, et al (2011). Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol, 29, 3307-15.   DOI   ScienceOn
75 Scagliotti GV, Novello S, Schiller JH, et al (2012) A phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, nonsmall- cell lung cancer. Clin Lung Cancer, 13, 391-5.   DOI
76 Scagliotti GV, Selvaggi G, Novello S, et al (2004). The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res, 10, 4227-4232.   DOI   ScienceOn
77 Sequist LV, Besse B, Lynch TJ, et al (2010). Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-smallcell lung cancer. J Clin Oncol, 28, 3076-83.   DOI   ScienceOn
78 Sequist LV, Waltman BA, Dias-Santagata D, et al (2011). Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 75ra26.
79 Seto T, Kiura K, Nishio M, et al (2013). CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol, 14, 590-8.   DOI
80 Shaw AT, Camidge DR, Engelman JA, et al (2012). Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC). J Clin Oncol , 30, [Epub ahead of print].
81 Shaw AT, Mehra R, Kim DW, et al (2013). Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol, 31, [Epub ahead of print].
82 Shaw AT, Solomon B, Kenudson MM (2011). Crizotinib and testing for ALK. J Natl Compr Canc Netw, 9, 1335-1341.   DOI
83 Siegelin MD, Borczuk AC (2014). Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest, 94, 129-37.
84 Shaw AT, Solomon B (2011). Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res, 17, 2081-6.   DOI   ScienceOn
85 Shaw AT, Yeap BY, Mino-Kenudson M, et al (2009). Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 27, 4247-53.   DOI
86 Shtivelman E, Hensing T, Simon GR, et al (2014). Molecular pathways and therapeutic targets in lung cancer. Oncotarget, 5, 1392-433.   DOI
87 Simmons BH, Lee JH, Lalwani K, et al (2012). Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lungadenocarcinoma tumors in Kras(G12D-LSL) mice. Cancer Chemother Pharmacol, 70, 213-20.   DOI
88 Singh RP, Deep G, Chittezhath M, et al (2006). Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst, 98, 846-55.   DOI   ScienceOn
89 Song T, Yu W, Wu SX (2014). Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI? Asian Pac J Cancer Prev, 15, 205-13.   DOI
90 Spira A and Ettinger DS (2004). Multidisciplinary management of lung cancer. New England Journal of Medicine, 350, 379-92.   DOI
91 Suda K, Tomizawa K, Mitsudomi T (2010). Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev, 29, 49-60.   DOI
92 Travis WD, Brambilla E, Noguchi M, et al (2011). International association for the study of lung cancer/american thoracic society/european respi¬ratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol, 6, 244-85.   DOI
93 Swanton C, Futreal A, Eisen T (2006). Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res, 12, 4377-83.   DOI
94 Takeuchi K, Choi YL, Togashi Y, et al (2009). KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistrybased diagnostic system for ALK-positive lung cancer. Clin Cancer Res, 15, 3143-9.   DOI
95 Takeuchi K, Soda M, Togashi Y, et al (2012). RET, ROS1 and ALK fusions in lung cancer. Nature Med, 18, 378-81.   DOI   ScienceOn
96 Ulasli SS, Celik S, Gunay E, et al (2013). Anticancer effects of thymoquinone, caffeic acid phenethyl ester and resveratrol on A549 non-small cell lungcancer cells exposed to benzo(a) pyrene. Asian Pac J Cancer Prev, 14, 6159-64.   DOI   ScienceOn
97 Usuda K, Sagawa M, Motono N, et al (2014). Relationships between EGFR mutation status of lung cancer and preoperative factors-are they predictive? Asian Pac J Cancer Prev, 15, 657-62.   DOI   ScienceOn
98 Walter AO, Tjin R, Haringsma H, et al (2011). CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M resistance mutations. Mol Cancer Ther, 10.
99 Wang H, Wu H, Cai K, et al (2012). Phosphatidylinositol 3-kinase could be a promising target in lung cancer therapy. J BUON, 17, 729-34.
100 Wang JY and Cai Y (2013). Clinical observation and prognostic analysis of pemetrexed plus platinum as first-line treatment in patients withadvanced non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 6267-71.   DOI   ScienceOn
101 Winter H, van den Engel NK, Rusan M, et al (2011). Activespecific immunotherapy for non-small cell lung cancer. J Thorac Dis, 3, 105-14.
102 Wong KK, Fracasso PM, Bukowski RM, et al (2009). A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res, 15, 2552-8.   DOI
103 Yamamoto H, Shigematsu H, Nomura M, et al (2008). PIK3CA mutations and copy number gains in human lung cancers. Cancer Res, 68, 6913-21.   DOI
104 Zhang Z, Stiegler AL, Boggon TJ,et al (2010). EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget, 1, 497-514.   DOI
105 Zou ZQ, Zhang LN, Wang F, et al (2012). The novel dual PI3K/ mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lungcancer cells. Mol Med Rep, 5, 503-8.
106 Anish Thomas A, Hassan R (2012) Immunotherapies for nonsmall-cell lung cancer and mesothelioma. Lancet Oncology, 13, 301-10.   DOI
107 Alimujiang S, Zhang T, Han ZG, et al (2013). Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as maintenance therapy for advanced non- small-cell lung cancer: a meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev, 14, 2413-9.   DOI   ScienceOn
108 Ana Christina GC, Enriqueta F (2013). HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. Transl Lung Cancer Res, 2, 122-7.
109 Ancuceanu RV, Istudor V (2004) Pharmacologically active natural compounds for lung cancer. Altern Med Rev, 9, 402-19.
110 Antonicelli A, Cafarotti S, Indini A, et al (2013). EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. Int J Med Sci, 10, 320-30.   DOI
111 Arcila ME, Oxnard GR, Nafa K, et al (2011). Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of theT790M mutation using a locked nucleic acid-based assay. Clin Cancer Res, 17, 1169-80.   DOI
112 Balak MN, Gong Y, Riely GJ, et al (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res, 12, 6494-501.   DOI
113 Cai Y, Sheng ZY, Chen Y, et al (2014) Effect of Withaferin A on A549 cellular proliferation and apoptosis in non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1711-4.   DOI
114 Bergethon K, Shaw AT, Ou SH, et al (2012). ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol, 30, 863-70.   DOI
115 Bethune G, Bethune D, Ridgway N, et al (2010). Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis, 2, 48-51.
116 Yang C, Shih J, Chao T, et al (2008). Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial. J Clin Oncol, 26, [Epub ahead of print].
117 Cao W, Li AW, Ren SX, et al (2014). Efficacy of first-line chemotherapy affects the second-line setting response in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 6799-804.   DOI
118 Cappuzzo F, Marchetti A, Skokan M, et al (2009). Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancerpatients. J Clin Oncol, 27, 1667-74.   DOI
119 Cardarella S, Johnson B (2013). The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med, 188, 770-5.   DOI
120 Chen S, Flower A, Ritchie A, et al (2010). Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review. Lung Cancer, 68, 137-45.   DOI
121 Choi YL, Takeuchi K, Soda M, et al (2008). Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res, 68, 4971-6.   DOI